Skip to main content

Table 3 Univariable and multivariable analyses of relapse-free survival

From: Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes

 

n

Univariable analysis HR (95% CI)a

p value

Multivariable analysis HR (95% CI)a

p value

Menopausal status

 Pre-

360

1.365 (0.958–1.985)

0.086

  

 Post-

703

1.00

   

Tumor size

 ≤ 2.0 cm

639

1.00

< 0.0001

1.00

< 0.0001

 > 2 cm

426

2.964 (2.135–4.157)

 

2.410 (1.645–3.575)

 

Lymph node metastasis

 Negative

743

1.00

< 0.0001

1.00

< 0.0001

 Positive

317

2.990 (2.160–4.154)

 

2.568 (1.742–3.800)

 

Tumor grade

 1

561

1.00

0.0003

1.00

0.014

 2+3

479

1.859 (1.331–2.624)

 

1.627 (1.101–2.420)

 

Estrogen receptor status

 Positive

853

1.00

< 0.0001

1.00

0.024

 Negative

223

2.089 (1.471–2.925)

 

1.964 (1.094–3.610)

 

Progesterone receptor status

 Positive

735

1.00

< 0.0001

1.00

0.843

 Negative

336

1.946 (1.406–2.681)

 

1.054 (0.614–1.736)

 

HER2 status

 Negative

897

1.00

 

0.186

 

 Positive

162

1.345 (0.861–2.022)

   

Chemotherapy

 No

512

1.00

0.0221

1.00

0.0021

 Yes

512

1.480 (1.107–2.201)

 

0.509 (0.335–0.780)

 

CEA levelb

 Low

885

1.00

< 0.0001

1.00

0.047

 High

191

2.415 (1.057–2.091)

 

1.520 (1.005–2.245)

 

CA15-3 levelc

 Low

762

1.00

< 0.0001

1.00

< 0.0001

 High

314

2.824 (2.050–3.887)

 

2.088 (1.457–2.901)

 
  1. aHazard ratio (95% confidence interval)
  2. bHigh: ≥ 3.2ng/mL, low < 3.2 ng/mL
  3. cHigh: ≥ 13.3 U/mL, low < 13.3 U/mL